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A moderate elevation of circulating levels
of IGF-I does not alter ErbB2 induced
mammary tumorigenesis
Robert K Dearth1,2, Isere Kuiatse1, Yu-Fen Wang1, Lan Liao3, Susan G Hilsenbeck1, Powel H Brown1, Jianming Xu3
and Adrian V Lee1*
Abstract
Background: Epidemiological evidence suggests that moderately elevated levels of circulating insulin-like growth
factor-I (IGF-I) are associated with increased risk of breast cancer in women. How circulating IGF-I may promote
breast cancer incidence is unknown, however, increased IGF-I signaling is linked to trastuzumab resistance in ErbB2
positive breast cancer. Few models have directly examined the effect of moderately high levels of circulating IGF-I
on breast cancer initiation and progression. The purpose of this study was to assess the ability of circulating IGF-I
to independently initiate mammary tumorigenesis and/or accelerate the progression of ErbB2 mediated mammary
tumor growth.
Methods: We crossed heterozygous TTR-IGF-I mice with heterozygous MMTV-ErbB2 mice to generate 4 different
genotypes: TTR-IGF-I/MMTV-ErbB2 (bigenic), TTR-IGF-I only, MMTV-ErbB2 only, and wild type (wt). Virgin females
were palpated twice a week and harvested when tumors reached 1000 mm3. For study of normal development,
blood and tissue were harvested at 4, 6 and 9 weeks of age in TTR-IGF-I and wt mice.
Results: TTR-IGF-I and TTR-IGF-I/ErbB2 bigenic mice showed a moderate 35% increase in circulating total IGF-I
compared to ErbB2 and wt control mice. Elevation of circulating IGF-I had no effect upon pubertal mammary
gland development. The transgenic increase in IGF-I alone wasn’t sufficient to initiate mammary tumorigenesis.
Elevated circulating IGF-I had no effect upon ErbB2-induced mammary tumorigenesis or metastasis, with median
time to tumor formation being 30 wks and 33 wks in TTR-IGF-I/ErbB2 bigenic and ErbB2 mice respectively (p =
0.65). Levels of IGF-I in lysates from ErbB2/TTR-IGF-I tumors compared to ErbB2 was elevated in a similar manner to
the circulating IGF-I, however, there was no effect on the rate of tumor growth (p = 0.23). There were no
morphological differences in tumor type (solid adenocarcinomas) between bigenic and ErbB2 mammary glands.
Conclusion: Using the first transgenic animal model to elevate circulating levels of IGF-I to those comparable to
women at increased risk of breast cancer, we showed that moderately high levels of systemic IGF-I have no effect
on pubertal mammary gland development, initiating mammary tumorigenesis or promoting ErbB2 driven
mammary carcinogenesis. Our work suggests that ErbB2-induced mammary tumorigenesis is independent of the
normal variation in circulating levels of IGF-I.
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Background
IGF-I has the characteristics of both a circulating
hormone and a tissue growth factor. While numerous
studies have focused on the autocrine and/or paracrine
ability of IGF-I to regulate mammary gland development
and tumorigenesis [1], only a few have focused on the
role of circulating IGF-I [2]. Although it is known that
circulating levels of IGF-I vary considerably within the
normal population, meta-analysis of several studies have
shown that elevated serum IGF-I levels are associated
with increased risk of breast cancer in premenopausal
women [3]. Mammographic density is strongly related
to breast cancer risk [4] and evidence supports a posi-
tive correlation between circulating IGF-I levels and
mammographic density [5]. Supporting this, the IGF-I
axis correlates with birth weight, height, and parity, all
which have been show to be contributing breast cancer
risk factors [6,7]. Increased IGF-I signaling has also
been linked to trastuzumab resistance in ErbB2 positive
breast cancer [8] and blocking both the IGF-I receptor
(IGF-IR) and the ErbB2 receptor (ErbB2-R) inhibits
ErbB2 driven breast cancer cell growth [9]. Conversely,
antiestrogens that are effective in the treatment and pre-
vention of breast cancer have been consistently found to
lower serum IGF-I levels [10].
The idea that circulating IGF-I may regulate breast
cancer is persuasive, especially taking into account that
IGF-I, mediated by the endocrine actions of growth hor-
mone (GH), plays a vital role in regulating the developing
mammary gland [11]. The mammary gland can prolifer-
ate in response to IGF-I both in organ culture [12], and
by treatment of mice with an implant containing IGF-I in
the mammary gland [13]. Conversely, it has been shown
that there is very limited growth of IGF-IR-null mam-
mary epithelium [14]. In addition, IGF-I-null mice have
severely retarded mammary ductal development and
branching [11]. These and other studies support a model
whereby GH acts upon mammary stroma which pro-
duces IGF-I to stimulate pubertal mammary ductal out-
growth in a paracrine manner. However, recent studies
in mice with only circulating IGF-I and no local produc-
tion have shown that endocrine IGF-I can also support
mammary ductal growth [15,16]. We have previously
shown that circulating IGF-I, via tail vein administration,
results in activation of IGF signaling in the mammary
gland [17]. Conversely, using a novel GH antagonist, peg-
visomant, we showed that blocking GH action, which
results in a lowering of serum IGF-I levels can block
IGF-I signaling in the mammary gland and results in a
delay of mammary gland development [18].
It has been shown that little (lit/lit) mice, which have
only 10% of circulating IGF-1 levels, displayed a signifi-
cant reduction of growth of human MCF-7 cell
xenografts [19]. Similarly, deletion of the IGF-I gene in
the liver, resulting in an 80% reduction in circulating
IGF-I, delays chemically and transgenically-induced
mammary tumorigenesis and metastasis[20]. As compel-
ling as these studies may be in supporting the notion
that reduced circulating IGF-I may limit breast cancer
initiation and progression, the 10% level of circulating
IGF-I doesn’t mimic epidemiologic studies.
There are few mouse models that show moderate
changes in circulating IGF-I that are comparable to
human variation. We originally developed TTR-IGF-I
transgenic mice which overexpress IGF-I mRNA exclu-
sively in the liver and show a moderate but significant
increase in circulating levels of IGF-I [21]. Importantly
the 35% increase in circulating IGF-I demonstrated in
this model is comparable to the 31% increase in circu-
lating IGF-I levels shown to increase breast cancer risk
in premenopausal women [22]. The increase in our
model is significantly less than the 2.5-fold increase seen
in a similar TTR-IGF-I model recently reported by Wu
et al. [15]. To determine if increased levels of IGF-I can
initiate mammary tumorigenesis and/or promote ErbB2-
induced tumorigenesis, we crossed TTR-IGF-I trans-
genic mice with the well characterized MMTV-ErbB2
transgenic mice. Increased circulating IGF-I did not
alter pubertal mammary gland development or total
body composition. We show that although TTR-IGF-I
and bigenic mice had a 35% increase in circulating total
IGF-I compared to ErbB2 transgenic and control mice,
IGF-I alone was insufficient to cause mammary tumori-
genesis. Furthermore, the elevation of systemic IGF-I
had no effect on ErbB2-induced mammary tumorigen-
esis. Analysis of ErbB2-intiated tumors revealed no
major effect of increased circulating IGF-I on tumor
type (solid adenocarcinomas) or mammary gland signal-
ing. This is the first study using a transgenic animal
model that mimics the variation of normal circulating
levels of IGF-I in epidemiological studies. Our studies
show that elevated circulating IGF-I has no effect on
normal mammary gland development or ErbB2-induced
mammary tumorigenesis.
Methods
Animals and Experimental Design
All animals were housed under controlled conditions of
temperature (23°C), lights (lights on: 0600 h; lights off:
1800 h) and ad libitum access to food (Harland Teklad
Diet, Madison, WI) and tap water. The care and hand-
ling of animals used in this study followed the guidelines
established by the National Institutes of Health (NIH)
and all humane procedures were pre-approved by the
University Laboratory Animal Care Committee
(ULACC).
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Homozygous TTR-IGF-I (tg/tg) transgenic females on
a C57/Bl6 background were developed and characterized
previously [21]. Due to the known ability of the C57/Bl6
genetic background to inhibit oncogene-induced mam-
mary tumorigenesis[23], homozygous TTR-IGF-I mice
were first backcrossed to FVB/N mice for six genera-
tions to create homozygous TTR-IGF-I/FVB/N animals
in order to cross these animals with the ErbB2 mouse
model MMTV-c-Neu FVB/N. MMTV-c-Neu FVB/N
mice (Jackson Laboratories) are based on a mammary
specific overexpression of the ErbB2 receptor (a fre-
quently amplified oncogene in human breast cancer),
which results in mammary specific tumorigenesis[24].
Homozygous TTR-IGF-I and homozygous MMTV-c-
Neu FVB/N (further referred to as MMTV-ErbB2) mice
were crossed to FVB/N wild type mice to produce het-
erozygous transgenics. For mammary gland developmen-
tal studies heterozygous TTR-IGF-I (tg/wt) FVB females
and age-matched wild type FVB/N littermates (controls)
were sacrificed at 4 weeks, 6 weeks and 9 weeks of age.
Blood was collected and mammary glands processed for
paraffin blocks or whole mount analysis.
For the tumor studies heterozygous TTR-IGF-I (tg/wt)
mice were crossed with heterozygous MMTV-ErbB2
(tg/wt) mice. The resulting offspring had one of 4 geno-
types; heterozygous TTR-IGF-I (tg/wt), heterozygous
MMTV-ErbB2 (wt/tg), bigenic TTR-IGF-I/MMTV-
ErbB2 (tg/tg), or wild type controls (wt/wt). Female
were weaned at 21 days and housed five per cage and
monitored for mammary gland tumorigenesis. In all stu-
dies age-matched wild type littermates were used as
controls.
Mice were palpated twice weekly to determine time to
tumor formation, and once palpated, the rate of tumor
growth was determined by measuring the tumor size
with caliper measurements (millimeters/mm) and using
the formula for an ellipsoid sphere: L × W2/2 = mm3.
Mice were sacrificed when tumors reach 1000 mm3.
Once tumors reached 1000 mm3, mice were injected
with BrdU (100 mg/kg) for 2 hrs, sacrificed; and normal
mammary glands and mammary glands with tumors
were processed for paraffin blocks or frozen in liquid
nitrogen.
Whole gland morphological and histological analysis
For tumor and developmental studies mammary gland
whole mounts were processed as previously described
by Williams and Daniel [25] with the following modifi-
cations. The #4 inguinal mammary glands from the
right side were removed and spread flatly on the inner
surface of a 50 ml tube and fixed with with 10% Forma-
lin in PBS. The next day, tissue was placed in a cassette
and fat was removed using acetone for 48 hrs. Samples
were dehydrated in 100% ethanol (EtOH) for l hr, 95%
EtOH for 1 hr, and stained with Carmine Alum. Mam-
mary glands were destained as follows: H20 for 1 hr.;
70% EtOH for 1 hr.; 95% EtOH for 1 hr.; 100% EtOH 3
× for 1 hr.; and cleared in xylene 3 × for 1 hr. Finally
tissues were permanently stored in glass vials filled with
methylsalicylate until analyzed.
Percentage of fat pad filled was determined by mea-
suring (mm) the length of ductal out growth of #4 ingu-
inal normal mammary glands and dividing it by the
length of the total length of the mammary gland fat pad
at 4, 6 and 9 weeks of age.
Mammary gland tumors and #4 inguinal normal
mammary glands were harvested, placed in cassettes
and fixed in 4% paraformaldehyde in PBS overnight.
The following day, paraformaldehyde was replaced by
70% EtOH and samples were embedded in paraffin.
Serial sections (5 μm thick) cut from paraffin blocks
were placed on Superfost Plus slides (Fisher Scientific,
Fair Lawn, NJ), deparaffinized, gradually hydrated and
all sections stained with Hematoxylin-Eosin (H&E) and
then examined microscopically.
Immunoblot analysis
Frozen mammary glands were first crushed under liquid
nitrogen using a metal pestle and mortar. Crushed tissue
was lysed in TNESV buffer and 50 μg of tissue protein
lysate was immuonblotted as described previously [26].
We used the following antibodies at the listed concen-
trations: Anti-P85 1:1000 (Upstate Group, Inc., Lake
Placid, NY, USA), p-AKT 1:1000 (Cell Signaling Tech-
nology, Beverly, MA, USA), p-ERK1/2 1:1000 (Cell Sig-
naling Technology, Beverly, MA, USA), AKT 1:1000
(Cell Signaling Technology, Beverly, MA, USA), ERK1/2
1:4000 (Upstate Group, Inc., Lake Placid, NY, USA), and
b-actin 1:4000 (BD Biosciences, San Jose, CA, USA).
Hormone Assays
IGF-I levels were measured in serum using rat/mouse
IGF-I ELISA assay purchased from Immunodiagnostic
Systems (Boldon, Tyne & Wear, UK). The assay sensitiv-
ity was 82 ng/ml. IGF-I levels measured in mammary
gland tissue were measured by first crushing the tissue
under liquid nitrogen using a metal pestle and mortar.
Crushed tissue was then lysed in TNESV buffer and 10
μl of supernatant was assayed by a newly developed
mouse IGF-I High Sensitivity (HS) ELISA assay from
Immunodiagnostic Systems. The assay sensitivity was
2.8 ng/ml.
Statistical Analysis
In the tumor studies, weights between animals that
expressed the TTR-IGF-I transgene (TTR-IGF-I and
TTR-IGF-I/MMTV-ErbB2 bigenics) and those that did
not (wild type and MMTV-ErbB2 trangenics) were
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analyzed using ANOVA. All other analysis was done by
unpaired Student’s t test assuming random sampling.
Probability values < 0.05 were considered to be statisti-
cally significant. The IBM PC programs INSTAT and
PRISM software (GraphPad, San Diego, CA, USA) were
used to calculate and graph the results. Time to tumor
formation was analyzed using Kaplan-Meier survival
curves [27] and compared using the generalized Wil-
coxon test [28]. Tumor growth rates were analyzed by
computing the individual growth curve measurements
from time of primary tumor appearance to attaining a
size of 500 mm3. Then the growth rates for each mouse
were compared using a Student’s t test.
Results and Discussion
A moderate increase in levels of circulating IGF-I doesn’t
alter pubertal mammary gland development
To examine the effect of elevated circulating IGF-I on
pubertal mammary gland development and tumorigen-
esis, we crossed TTR-IGF-I heterozygous mice with
MMTV-ErbB2 heterozygous mice. MMTV-ErbB2 mice
are based on mammary specific overexpression of the
ErbB2 receptor (a frequently amplified oncogene in
human breast cancer), which results in mammary speci-
fic tumorigenesis [24]. The resulting offspring had one
of 4 genotypes; increased systemic IGF-I only (Tg/wt),
mammary specific ErbB2 overexpression only (wt/tg),
both systemic IGF-I and mammary ErbB2 bigenic
expression (tg/tg), or wild type controls (wt/wt). At 4
weeks of age there was a significant 9.5% increase in cir-
culating IGF-I levels in TTR-IGF-I transgenic females
(942.54 ± 21.57 ng/ml) compared to age matched con-
trols (860.91 ± 20.79 ng/ml) (data not shown). At 6
weeks of age, TTR-IGF-I transgenic mice (TTR-IGF-I
and TTR-IGF-I/ErbB2) showed a 35% increase in circu-
lating IGF-I compared to mice without the TTR-IGF-I
transgene (wt and ErbB2) (941.22 ±41.77 ng/ml vs.
743.69 ± 28.24 ng/ml - Figure 1A). As expected the
ErbB2 transgene did not affect the TTR-IGF-I trans-
genic stimulation of increased circulating IGF-I in these
animals. The increase in IGF-I caused a significant
increase (p < 0.05) in overall body growth in animals
expressing the TTR-IGF-I transgene during weeks 7, 10-
12, however, body weight was equal afterwards (Figure
1B). Interestingly, a minor sustained increase in body
growth in TTR-IGF-I trangenics was observed through-
out the time of mammary gland development. We pre-
viously reported that homozygous TTR-IGF-I on a
C57BL/6 genetic background had a 50% elevation of cir-
culating IGF-I and resulted in a similar 10% increase in
female bodyweight during weeks 8, 10-12 [21]. The
lower level of circulating IGF-I in heterozygous TTR-
IGF-I/FVB/N mice might be due to the use of heterozy-
gous mice, or the FVB/N genetic background. The lack
of a dramatic sustained growth difference in TTR-IGF-I/
C57BL/6 or TTR-IGF-I/FVB/N is interesting and may
reflect a threshold of IGF-I needed to observe a sizable
difference. In a similar manner, previous studies shown
that deletion of the liver IGF-I resulted in a dramatic
reduction in circulating IGF-I but had no effect upon
normal growth, and it wasn’t until the acid labile subu-
nit (ALS) was also deleted that levels went below a
threshold needed to see an effect upon overall body
growth [29,30].
Whole mount analysis revealed that higher levels of sys-
temic IGF-I had no effect upon the developing mammary
gland compared to controls at 4, 6 and 9 weeks of age
(Figure 2). More specifically, 26% of the mammary fat pad
in the control (wt) and 28% in the TTR-IGF-I (tg) groups
was filled with a developing ductal tree by 4 weeks of age.
Similar ductal growth patterns between the two groups
were also observed at 6 and 9 weeks of age, which is sum-
marized in Table 1. The lack of effect of circulating IGF-I
on mammary gland development is consistent with a pre-
vious studying showing that it is paracrine mammary
gland IGF-I that is primarily responsible for ductal devel-
opment [31]. Supporting this, ductal branching is signifi-
cantly reduced in mammary glands from adult transgenic
IGF-Im/m mice which have a multi-tissue (including mam-
mary gland) reduction in IGF-I production. However, in
IGF-I LID transgenic mice (deletion of liver-specific IGF-I)
mammary gland branching is unaffected by the 75%
reduction in circulating IGF-I [32]. Thus, it is unclear how
much circulating IGF-I is actually reaching the mammary
gland. It is possible that IGF-I is bound up, by IGF-I bind-
ing proteins (BP), in the extracellular matrix of the mam-
mary gland and is unable to bind to IGF-IR. In our initial
characterization of the TTR-IGF-I mouse, liver overex-
pression of IGF-I was also associated with increased circu-
lating levels of IGF-I BP3 [21], which may inhibit the
ability of free circulating IGF-I to act on the mammary
gland promoting growth and subsequent tumorigenesis.
Interestingly, the hepatic IGF-I transgenic mouse (HIT)
generated on the FVB/N background which has liver-spe-
cific production of circulating IGF-I (resulting in a 2.5-fold
increase in circulation IGF-I without an increase in hepatic
IGFI-BP3 or ALS [15] levels) has been shown to increase
mammary gland proliferation and cause hyperplasia at 6
to 8 wks of age [16]. In the same study, Cannata et al.
[16], showed that mice with transgenically increased circu-
lating IGF-I, but no tissue IGF-I (KO-HIT), mammary
gland proliferation was comparable to controls at 6 to 8
wks of age. Furthermore, the authors noted an increase in
ductal branching at 4 and 16 weeks of age but not at 8
wks of age in HIT mice, whereas circulating IGF-I in KO-
HIT mice can support mammary gland growth during this
period without local IGF-I [16]. HIT mice have been
shown to rescue developmental growth in IGF-I null mice
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but not correct reproductive deficiencies in these animals
as a result of the absence of tissue IGF-I [15].These studies
are compelling and support the notion that that circulat-
ing IGF-I has the ability to promote morphological
changes in mammary gland development, particularly in
the absence of local IGF-I. Importantly, no studies to date
have shown that a systemic increase in circulating IGF-I
can initiate and/or promote mammary tumorigenesis.
Increased circulating IGF-I doesn’t affect mammary gland
tumorigenesis
Bigenic IGF-I/ErbB2 virgin female mice showed palpable
mammary tumors beginning at 24 weeks of age and had
a mean time to tumor formation (MTTF) of 33 weeks
(Figure 3A). ErbB2 only transgenic virgin females
showed a similar tumor formation with the earliest
mammary tumors palpated at 24 weeks of age and a
MMTF of 30 weeks (Figure 3A). There was no differ-
ence in MTTF (p = 0.59). Importantly, increased circu-
lating levels of IGF-I had no affect on mammary tumor
incidence, as no mammary tumors were detected in the
TTR-IGF-I only mice (Figure 3A). While species varia-
tion in IGF-I signaling may play a role in our findings
compared to epidemiological data that currently exists
[3] a wealth of evidence confirms the common function-
ality of IGF-I signaling between humans and mice in
both normal growth and development, and numerous
human malignancies not just breast cancer [33].
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Figure 1 Liver specific transgene overexpression of IGF-I results in increased levels of circulating IGF-I and increased body weight. A.)
Overexpression of liver IGF-I (black bar) resulted in a significant (p < 0.01) increase in female serum levels of IGF-I measured at 6 weeks of age
compared to mice without the TTR-IGF-I transgene (white bar). B.) Females expressing the IGF-I transgene exhibited significantly (p < 0.05) larger
body weights at 7, 10-12 weeks of age due to increased circulating IGF-I compared to wt/ErbB2 only controls. No transgene = wt + ErbB2 only
females; IGF-I Transgene = TTR-IGF-I transgenic + TTR-IGF-I-ErbB2 bigenic females. N for each group is represented within their respective bars.
N = 30 animals per group for weight. ** p < 0.01; * p < 0.05.
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Mammary tumors from bigenic mice had signifi-
cantly (p < 0.05) higher bioavailable IGF-I protein
levels (110.84 ± 9.02) compared to mammary tumors
from ErbB2 only mice (73.97 ± 9.01) measured by
ELISA (Figure 3B). This elevation mimicked the
significantly increased (p < 0.05) circulating levels of
IGF-I measured in these animals (Figure 3B) and were
similar to the elevated levels in TTR-IGF-I animals at
6 wks of age (Figure 1A). However, there was no dif-
ference in IGF-I protein levels in the contralateral
normal mammary glands (no detectable tumor) from
the same animals (Figure 3B). The observed increase
in IGF-I in the bigenic tumors might simply be a
result of contamination from blood due to increased
blood flow in the tumors. However, it is also plausible
that the TTR-IGF-I transgene was activated in the
tumors resulting in increased paracrine IGF-I protein
levels which may have contributed to the measured
increase of IGF-I in these tumors. Given this, we care-
fully examined the growth rate of the tumors to test if
the increased IGF-I might alter tumor progression.
Therefore the rate of tumor growth was assessed by
comparing the tumor size (mm3) vs. the age in days of
all individual tumors in both the ErbB2 (left panel)
and bigenic groups (right panel; Figure 4). However,
Figure 4 clearly illustrates that increased levels of IGF-
I had no effect on the growth of ErbB2 tumors in
these animals (p = 0.23).
A complete analysis of the groups revealed that 95%
(19 of 20) of the bigenics and 90% (19 of 21) of the
ErbB2 only transgenic mice developed mammary
tumors. Furthermore, both groups of mice averaged
approximately the same number of mammary tumors
per animal (ErbB2 - 2.2 tumors/mouse and bigenic 2.3
tumors per mouse). This data is summarized in Table 2.
Whole mount (data not shown) and H&E analysis
revealed no major morphological differences in ductal
branching and tumor type (solid adenocarcinomas)
between bigenic and ErbB2 mammary glands at the
time tumors were harvested (Figure 5A). Furthermore,
immunoblot analysis revealed that circulating levels of
IGF-I seemingly had no effect on mammary gland sig-
naling (Figure 5B). As expected, AKT phosphorylation
was elevated in mammary gland tumors from both
bigenic and ErbB2 females. There were no observable
differences in ERK1/2 protein expression in mammary
gland tumors from either group. More importantly,
increased circulating IGF-I had no effect on normal
mammary gland signaling compared to groups that did
not express the TTR-IGF-I transgene (Figure 5B). Our
Wt-6wks
TTR-IGF-I-6wks
Wt-4wks
TTR-IGF-I-4wks
Wt-9wks
TTR-IGF-I-9wks
Figure 2 Increased circulating levels of IGF-I had no effect on
pubertal mammary gland growth. Representative whole mounts
of wild type (wt) and IGF-I transgenic (TTR-IGF-I) mammary glands
at 4 wks (top 2 panels), 6 wks (middle 2 panels), and 9 wks of age
(bottom 2 panels). N = 20 per group at 4 wks of age; N = 4 for WT
and N = 7 for TG at 6 wks of age; N = 7 for WT and N = 8 for TG
at 9 wks of age. WT = wild type and TG = TTR-IGF-I.
Table 1 Analysis of Mammary Gland Growth
Group Wild Type (control) Transgenic (TTR-IGF-I)
Average. % Fat Pad Filled 4 wks 26% 28%
Average. % Fat Pad Filled 6 wks 80% 87%
Average. % Fat Pad Filled 9 wks 82% 82%
There was no difference in mammary gland development compared to age-matched wild types at 4, 6 and 9 weeks of age as determined by percent of the
mammary fat pad filled with the ductal tree. N = 20 for WT and TG at 4 wks of age; N = 4 for WT and 7 for TG at 6 wks of age; N = 7 for WT and N = 8 for TG
at 9 wks of age. WT = wild type and TG = TTR-IGF-I
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a significant increase (p < 0.05) in serum IGF-I in these same bigenic females compared to ErbB2 transgenics. Bars indicate the mean (±SEM)
serum or protein levels of IGF-I assayed by ELISA. N = indicated with bars; MG = Mammary Gland; ErbB2 = ErbB2 transgenic only; Bigenic = TTR-
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Figure 4 Increased circulating IGF-I does not alter growth in ErbB2-induced mammary gland turmors. Graphs plotting individual tumor
growth curves for ErbB2 (left) and bigenic (right) females. Statistical analysis revealed that increased circulating levels of IGF-I (right) had no
significant (p = 0.23) affect on mammary tumor growth compared to ErbB2 only induced mammary tumors. N = 16 for ErbB2 group and 15 for
TTR-IGF-I-ErbB2 bigenic group.
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findings are similar to a previous report showing that
elevated levels of circulating IGF-I in HIT mice did
not alter IGF-I regulated downstream signaling path-
ways [16].
Conclusions
Epidemiological data suggests that increased circulating
IGF-I is associated with a women’s risk of developing
breast cancer [3]. On the other hand, experimental evi-
dence that increased circulating IGF-I is able to initiate
and/or regulate tumor growth has not yet been estab-
lished. Using the first transgenic animal model to simu-
late circulating levels of IGF-I that may be comparable
to levels in women susceptible to breast cancer, our
data suggest that modest elevation of circulating IGF-I
do not have a role in mammary tumor initiation or pro-
motion. More so, we showed that circulating IGF-I does
not alter normal pubertal mammary gland development;
thus supporting the established dogma that paracrine/
autocrine IGF-I regulated by GH is the preferred regula-
tory pathway responsible for mammary gland develop-
ment [34].
The inability of increased circulating IGF-I to initi-
ate mammary tumorigenesis in our model suggest that
the breast cancer risk associated with higher levels of
circulating IGF-I in women may, in part, be due to
IGF-I being associated or modulating another risk fac-
tor for breast cancer. Thus IGF-I may enhance a
women’s sensitivity to oncogenic promoters like ER
(estrogen receptor) or ErbB2. IGF-I has been shown to
Table 2 Comparing Groups: End of study tumor summary
ErbB2 Bigenic IGF-I Wild Type
Number of Tumors 19(20) = 95% 19(21) = 90% 0(25) 0(22)
Mean Time to Tumor Formation (MTTF) 224 days 30 wks/7.5 m 233 days 33 wks/8.3 m NA NA
Average Number of Tumors per Animal 2.2 (11) = 55% 2.3 (13) = 60% NA NA
Number of tumors = animals that got mammary tumors (total number of animals) %- percentage of animals with mammary tumors per group; Average number
of tumors per animal = average number of mammary gland tumors per animal (number of animals with multiple tumors), %- percentage of animals with
multiple tumors per group. NA = not applicable. ErbB2 = MMTV-ErbB2 transgenic; Bigenic = TTR-IGF-I-ErbB2 bigenic; IGF-I = TTR-IGF-I transgenic; Wild Type =
control; wks = weeks; m = months.
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Figure 5 Increased levels of circulating IGF-I have no effect on tumor type or mammary gland signaling. A.) Representative H&E staining
of mammary tumors promoted by MMTV-ErbB2 (top) or TTR-IGF-I-ErbB2 bigenic (bigenic-bottom). Both groups had similar tumor phenotypes
which were predominantly adenocarcinomas. B.) Representative immunoblot of phosphorylated (p) and total (T) AKT and Erk ½ signaling in
normal mammary glands (M) and tumors (T). *** = p < 0.001; Magnification: 40 ×. C = representative wild type females; I = representative TTR-
IGF-I transgenic females
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increase transcriptional activation of ER in breast can-
cer cell lines increasing cellular sensitivity to the
actions of estrogen [35,36]. However, estrogen has
been shown to activate the IGF pathway in MCF7L
xenographs independent of the level of circulating
IGF-I [37]. Furthermore, we showed that increased
circulating IGF-I levels had no effect on ErbB2 pro-
moted mammary tumorigenesis. This would suggest
the local interaction between the between the ErbB2
and IGF-I pathways previously shown [9,38] is inde-
pendent of circulating IGF-I and more likely depen-
dent upon alterations in autocrine/paracrine signaling
pathways in the breast.
This work culminates to suggest that circulating IGF-I
itself may not be directly altering breast cancer risk and
thus may not be a suitable target for successful treat-
ment. Further studies are required in additional models
to determine if this result is common across other
breast cancer subtypes.
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